Rigel Pharmaceuticals 3Q 2026: Revenue $80.89M, EPS $0.65 — 10-Q Summary

Rigel’s third-quarter revenue rose 16% year over year, while net income declined as higher research and development and selling, general and administrative expenses outweighed revenue growth. Sales of REZLIDHIA and newly launched VEPPANU increased, while TAVALISSE growth was partly offset by lower…